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ABSTRACT: The rise of multi- and even totally antibiotic resistant
forms of Mycobacterium tuberculosis underlines the need for new
antibiotics. The pathogen is resistant to β-lactam compounds due to its
native serine β-lactamase, BlaC. This resistance can be circumvented by
administration of a β-lactamase inhibitor. We studied the interaction
between BlaC and the inhibitor clavulanic acid. Our data show
hydrolysis of clavulanic acid and recovery of BlaC activity upon
prolonged incubation. The rate of clavulanic acid hydrolysis is much
higher in the presence of phosphate ions. A specific binding site for
phosphate is identified in the active site pocket, both in the crystalline
state and in solution. NMR spectroscopy experiments show that
phosphate binds to this site with a dissociation constant of 30 mM in
the free enzyme. We conclude that inhibition of BlaC by clavulanic acid
is reversible and that phosphate ions can promote the hydrolysis of the inhibitor.
Mycobacterium tuberculosis (Mtb) is one of the most lethal
pathogens worldwide with 1.8 million deaths estimated in
2015.1 Despite promising recent developments,2 treatment of
the tuberculosis disease (TB) remains associated with long
duration and poor patient adherence. These factors have
accelerated the rise of multidrug resistant (MDR), extensively
drug resistant (XDR), and, recently, even totally drug resistant
(TDR) strains of Mtb.3 These strains pose a serious threat to
public healthcare, underlining the need for continued research
into Mtb resistance mechanisms and potential new medicines.
One potential drug strategy that has received attention is the
use of β-lactam/β-lactamase inhibitor combinations.4−6
Mtb possesses a native Ambler class A β-lactamase, BlaC,
that hydrolyses a broad spectrum of β-lactam antibiotics. The
innate resistance that BlaC confers to Mtb, together with the
availability of more effective treatment options, resulted in the
β-lactam class of antibiotics not being employed in the
treatment of Mtb infections. However, with antibiotic
effectiveness decreasing more rapidly than drug development
can counter, the broad range, proven safety, and ample
availability of β-lactam antibiotics may provide new oppor-
tunities for treatment of Mbt infection. In fact, resistance to β-
lactams can be circumvented by inhibition of BlaC by β-lactam-
like suicide substrates. The most common of these inhibitors is
clavulanic acid, and indeed, combinations of clavulanic acid
with β-lactam antibiotics were found to be bactericidal against
even XDR Mtb.7−10
Clavulanic acid inhibits BlaC in a substrate-like fashion,
forming a covalent bond with the catalytic serine (Ser-70 by
standard Ambler notation11). Generally, in class A β-lactamases,
it can then form a variety of covalently bound fragmentation
products in the active site, leaving the enzyme either transiently
or irreversibly inactivated.12 For BlaC, several of these products
have been found.13−15 Formation of these inactive forms was
initially reported to be irreversible in BlaC,13 but slow recovery
of activity was reported thereafter.16
A crystal structure of a covalent adduct formed between BlaC
and clavulanic acid was published by Tremblay et al.14
Interestingly, this structure models a well resolved phosphate
ion in the carboxylate binding site, immediately adjacent to the
bond between enzyme and adduct. At the same position, a
phosphate ion can also be found in several other BlaC crystal
structures.5,17−20 In fact, in 26 of the 29 BlaC crystal structures
that have been published to date, this position was found to be
occupied by either a phosphate ion or a carboxylate group of
the ligand that was used for cocrystallization. Additionally, Xu
et al. noticed that in their structure of BlaC with avibactam
(PDB: 4DF6), the sulfate group of the inhibitor occupied this
position.16 The authors of these studies either do not mention
the active site phosphate they model or assume that it is an
artifact of the high phosphate concentration under crystal-
lization conditions. We investigated the role of the phosphate
ion and demonstrate that it affects the rate of recovery from
clavulanic acid inhibition. We also show that a phosphate ion
binds to the enzyme in solution in the active site.
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■ MATERIALS AND METHODS
Materials. NMR analysis indicated that the nitrocefin
purchased from BioVision Inc. and Oxoid Limited was
significantly purer than that from Cayman Chemicals. The
BioVision nitrocefin was used in this study. Several values have
been reported for the change in extinction coefficient upon
hydrolysis of nitrocefin (e.g., refs 15, 21). To determine this
value independently, a stock solution containing 5.0 mg of
nitrocefin was diluted to a range of seven concentrations from
10 to 75 μM in 100 mM sodium phosphate buffer, pH 6.4. The
A486 values before and after complete hydrolysis by 20 min
incubation with 5 nM BlaC were determined. The slope of a
linear fit of ΔA486 against nitrocefin concentration yielded
Δε486. The procedure was performed in duplicate, yielding a
Δε486 of 17 ± 1 mM−1 cm−1. Clavulanic acid powder is
hygroscopic, so its concentration was determined by the
absorbance at 256 nm in NaOH. The extinction coefficient was
determined by quantitative NMR versus a standard of
trimethylsilylpropanoic acid. For ChemCruz and Matrix
clavulanic acid, which are sold in a cellulose matrix, we found
identical UV−vis spectra, yielding an absorbance at 256 nm of
20.0 ± 0.1 mM−1 cm−1. For TRC clavulanic acid, which is a
pure powder, the UV−vis spectrum is clearly different, and the
NMR spectrum shows impurities. The extinction coefficient at
256 nm is 18.7 mM−1 cm−1.
Production and Purification of BlaC. The blaC gene,
lacking codons for the N-terminal 42 amino acids that
constitute the signal peptide and with the addition of a C-
terminal histidine tag (Uniprot P9WKD3 modified as specified
in Figure S1), was expressed using a host optimized sequence
(ThermoFisher Scientific), cloned in the pET28a vector in
Escherichia coli BL21 (DE3) pLysS cells. The cells were
cultured in LB medium at 310 K until the optical density at 600
nm reached 0.6, at which point expression was induced with 1
mM IPTG and incubation continued at 289 K overnight. For
the production of isotope labeled proteins for NMR experi-
ments, LB medium was replaced with M9 medium (Table S1)
containing 15N ammonium chloride (0.3 g/L) as the sole
nitrogen source and, where necessary, 13C D-glucose (4.0 g/L)
and 2H2O (99.8%) as the carbon and hydrogen source,
respectively. Cells were harvested by centrifugation and lysed
with a French press in a buffer of 50 mM Tris-HCl pH 7.5
containing 500 mM NaCl. After centrifugation, the soluble
fraction was loaded on a HisTrap Nickel column (GE
Healthcare) and eluted with a gradient of 0−250 mM imidazole
in the same buffer. A Superose 12 10/300 GL size exclusion
chromatography column (GE Healthcare) was used for further
purification. Protein concentration and buffer exchange were
performed using 10 kDa cutoff Amicon Ultra centrifugal filter
units (Merck Millipore Ltd.). Protein purity was determined by
SDS-PAGE (Figure S3), and concentrations were determined
by the absorption at 280 nm, using the theoretical extinction
coefficient ε280 = 29 910 M
−1 cm−1.22 BlaC with a TEV-
cleavable His-tag (sequence specified in Figure S2) was
produced in the same way, with additional cleavage of the
purified protein by His-tagged TEV protease. Subsequent
repurification using another HisTrap Nickel column (GE
Healthcare) yielded pure, His-tag-less BlaC in the flowthrough.
Cleavage was confirmed by MS using a Waters Synapt
spectrometer yielding a mass of 28 637 ± 1 Da, corresponding
with 100% cleavage and 96% efficiency of the applied 15N-
labeling. No other protein forms, such as the noncleaved
construct (expected mass 31 770 Da at 96% 15N labeling), were
detected in the final sample.
Kinetics. All kinetic measurements were performed by
measuring hydrolysis of the chromogenic reporter substrate
nitrocefin at 486 nm, using a PerkinElmer Lambda 800 UV−vis
spectrometer thermostated at 298 K. To determine Michaelis−
Menten kinetic constants, initial nitrocefin hydrolysis rates by
5.4 nM BlaC were measured in 100 mM of the specified buffers,
in triplicate. OriginPro 9.1 was used to fit standard Michaelis−
Menten curves to these data. Reported are, for each condition,
the average and standard deviation of the three independent
fits.
The apparent first-order rate constants of inhibition (kiso)
were obtained by fitting the hydrolysis of 125 μM nitrocefin by
2 nM BlaC in the presence of various concentrations of
clavulanic acid against eq 1.13
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[P] Is the concentration of product in μM, vs and vi are the
final and initial reaction velocities in the presence of inhibitor in
μM s−1, respectively, t is time in s, and kiso is the apparent first-
order rate constant for the progression from vi to vs in s
−1.
Subsequently, the rate constants of inhibition were obtained by
fitting these data against eq 2,16 in which k3 and k2 are the rate
constants for step 3 and 2 in the conversion model (7) (see
Results), respectively, while Ki is the ratio k−1/k1 in that model.
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The data were also simulated using GNU Octave 3.2.4 and
numerical simulations of the differential equations derived from
the following model.
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where eqs 3 and 4 describe the conversion of nitrocefin (N)
and clavulanic acid (C), respectively. E is the enzyme, NE and
CE are the noncovalent complexes, and Ii and Pi represent the
covalent intermediates and the products, respectively. An
example script is provided as Supporting Information. Equation
4 is equivalent to the conversion model, discussed in the
Results (7).
Inhibition Recovery. All samples for inhibition recovery
experiments were thermostated at 298 K, at the concentrations
indicated in Table 3. Activity measurements were performed by
dilution in buffer without inhibitor to a final concentration of 2
nM BlaC with 100 μM nitrocefin. The time between initial
dilution and measurement was kept <5 min, and the reported
time is that of the measurement. Separate incubations were
performed to test the stability of BlaC without clavulanic acid,
as well as clavulanic acid without BlaC.
Mass Spectrometry. Samples for whole-protein mass
spectrometry were flash-frozen in liquid nitrogen and stored
at 193 K. Upon thawing, they were transferred to 10 mM
ammonium acetate buffer pH 6.8 using Micro Bio-Spin
chromatography columns (Bio-Rad), loaded on a C4 polymeric
reversed phase UPLC column and then analyzed using either
an LTQ-Orbitrap mass spectrometer (ThermoScientific) or a
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Synapt G2-Si mass spectrometer (Waters), 10−25 min after
thawing. Data were deconvoluted for charge using Thermo
Xcalibur.
Crystallization and Soaking Conditions. Crystallization
conditions for BlaC at a concentration of 20 mg mL−1 were
screened by sitting-drop vapor-diffusion using the JCSG+ and
PACT premier (Molecular Dimensions) screens at 293 K with
500-nL drops. The reservoir solution (75 μL) was pipetted by a
Genesis RS200 robot (Tecan), and the drops were made by an
Oryx6 robot (Douglas Instruments). Initial hits were obtained
in conditions D2 and D3 of the PACT premier screen, which
consist of 0.1 M 1:2:2-D/L-malic acid:MES:Tris base pH 5.0
and 6.0, respectively, and 25% polyethylene glycol (PEG) 1500.
Buffer optimization led to small needles in 0.1 M sodium
acetate buffer, pH 5.0, 25% PEG1500, which were resuspended
in 50 μL of the reservoir solution and crushed using a Seed
Bead-HR2−320 (Hampton). Crushed needles were diluted
1:10 in the same reservoir solution and used for seeding freshly
plated, 2-μL drops in the same conditions. Crystals useful for X-
ray diffraction grew within 4 days. The crystals were mounted
on cryoloops and cryo-protected by flash-cooling using liquid
nitrogen, either directly in mother liquor and 15% glycerol, or
after soaking for 50 min in mother liquor, 100 mM NH4H2PO4,
and 15% glycerol.
X-ray Data Collection and Structure Solving. X-ray data
collection was performed at the ESRF synchrotron-radiation
facility (Grenoble, France) on beamline ID30A-3 using a
PIXEL, Eiger_4 M (DECTRIS) X-ray detector. For structure
5OYO, a total of 4500 frames were collected, with an oscillation
of 0.05°, an exposure time of 0.02 s, total 90 s. For structure
5NJ2, a total of 3000 frames were collected, with an oscillation
of 0.1°, an exposure time of 0.01 s, total 30 s. The data sets
were autoprocessed by the EDNA23 Autoprocessing package
that used XDS24 to integrate the intensities and AIMLESS25 to
scale and merge the intensities in the mxCuBE26 to a resolution
of 2.1 and 1.19 Å for 5OYO and 5NJ2, respectively. The
structures were solved by molecular replacement with
MOLREP27 using 2GDN28 as a search model from the CCP4
suite29 and manually refined using REFMAC30 and Coot.31 Data
collection and refinement statistics are presented in Table S2.
Nuclear Magnetic Resonance Spectroscopy Experi-
ments. Samples for backbone assignment contained 0.75 mM
[15N,13C,2H] BlaC in 20 mM MES pH 6.0 with 1 mM DTT
and 6% D2O (NMR buffer) at 298 K. A set of standard HNCA,
HNCACB, HNcoCACB, HNCO, and HNcaCO experiments
was recorded on a Bruker AVIII HD 850 MHz spectrometer
equipped with a TCI cryoprobe for backbone assignment. All
other NMR spectra, unless stated otherwise, were recorded on
ca. 0.35 mM [15N] BlaC samples in the same buffer at 298 K,
on the same spectrometer. Data were processed with Topspin
3.2 (Bruker Biospin, Leiderdorp) and analyzed using CCPNmr
Analysis.32
NMR titrations were performed by addition of an increasing
volume of 0.9 M sodium phosphate or sodium chloride stock in
NMR buffer to the sample, decreasing protein concentration
from 0.35 to 0.25 mM during the titration. Nonlinear
regression fitting with a shared association constant (KA) and
individual maximal chemical shift perturbations (CSP) values
(CSPmax) in Origin 9.1 was used to fit the CSP data of selected
residues to eq 5, in which R is the ratio of phosphate
concentration over enzyme concentration, Cstock is the
concentration of the phosphate stock solution used for titrating
and Ei is the initial concentration of enzyme in the sample. The
phosphate titration was performed in duplicate. As the
interexperimental variation between samples was found to be
larger than the intraexperimental variation between reporter
peaks, data from the two experiments were fitted separately.
Reported are the average and standard deviation of the two fits.
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Samples for NMR visualization of BlaC recovery from
clavulanic acid inhibition contained 0.3 mM [15N] BlaC and 1.5
mM clavulanic acid in 100 mM MES or sodium phosphate
buffer, pH 6.4, with 1 mM DTT and 6% D2O, at 298 K.
Activity measurements as described above were performed at
various time points to check the relation between spectra and
functional states. Separate incubations were performed as
controls on the stability of BlaC without clavulanic acid, as well
as clavulanic acid without BlaC.
■ RESULTS
BlaC is normally produced by M. tuberculosis with an N-
terminal Tat-type signal peptide that is used to locate BlaC as a
lipoprotein on the outside of the cell membrane.33−35 To
obtain soluble protein for in vitro experiments, a BlaC gene
encoding only the soluble beta-lactamase domain supple-
mented with a C-terminal 6xHistidine purification tag was
expressed in E. coli. The protein was isolated and purified using
immobilized metal affinity chromatography and subsequent size
exclusion chromatography to yield ca. 30 mg BlaC per liter of
culture medium.
The Michaelis−Menten kinetic parameters of nitrocefin
hydrolysis by BlaC were determined in buffers with and without
phosphate (Table 1, Figure S4). The measured Michaelis
constant Km is higher in phosphate buffer than in the other
tested buffers. This effect appears to be somewhat compensated
by a higher catalytic efficiency at pH 6.
Our results are in agreement with previously published
kinetic values for BlaC nitrocefin hydrolysis, which have kcat/Km
in the range of (4−18) × 105 M−1 s−1.5,13,15,21 Similar to most
of these studies, further experiments have been performed at
pH 6.4, which is the optimum pH for BlaC. The work in this
study was performed on BlaC with a C-terminal His-tag (Figure
S1). To ensure that the tag has no effect on the activity, we also
prepared BlaC with a cleavable N-terminal His-tag (Figure S2).
The kinetic parameters of nitrocefin hydrolysis by BlaC without
His-tag were then compared to those of the His-tagged BlaC
used in this study and were found to be the same, at kcat/Km of
10 × 105 M−1 s−1 and 11 × 105 M−1 s−1, respectively, in 100
mM MES pH 6.4 (Table S3).
Table 1. Buffer Dependence of Nitrocefin Hydrolysis by
BlaCa
buffer kcat (s
−1) Km (μM) kcat/Km (× 10
5 M−1 s−1)
NaPi pH 6.0 107 ± 6 147 ± 14 7.3 ± 0.4
NaPi pH 7.0 64 ± 6 153 ± 23 4.2 ± 0.2
MES pH 6.0 69 ± 1 38 ± 7 18 ± 3
BIS-TRIS pH 6.0 83 ± 3 61 ± 7 14 ± 1
aBuffer concentrations were each 100 mM. Errors represent the
standard deviation over triplicate measurements.
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Next, BlaC inhibition by clavulanic acid was studied. For this,
Hugonnet and Blanchard proposed a reactivation model, eq 6,
including fast binding of the inhibitor I to the enzyme E to form
the EI complex, followed by slower conversion to the long-lived
EI* complex.13
+ *
− −
H Ioo H IooE I EI EI
k
k
k
k
1
1
2
2
(6)
Using this approach, they determined the affinity constant
for BlaC clavulanic acid inhibition (Ki = k−1/k1) to be 12.1 μM,
the inactivation rate k2 2.7 s
−1 and reactivation rate k−2
indistinguishable from zero. This led to the conclusion that
clavulanic acid inhibition of BlaC is irreversible. To study the
variation of inhibition kinetics with buffer conditions, we used
the reactivation model with the adjustment proposed by Xu et
al.16 (7), in which conversion of covalently bound clavulanic
acid EI* into a product P is allowed with a rate constant k3,
rather than reversal of the covalent linkage to the active site
serine residue with a rate constant k−2.
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As clavulanic acid acts as a slow-onset inhibitor for BlaC,
reaction rates can be estimated from the rate at which
enzymatic activity decreases upon administration of the
inhibitor. The resulting inhibition curves are plotted in Figure
1 for phosphate buffer and Figure S5 for MES buffer. These
data were fitted to eq 1 to obtain the apparent first-order rate
constants (kiso) of inhibition for each clavulanic acid
concentration, which were then fitted to eq 2 to estimate the
rate constants of inhibition (Table 2). The mathematical
description of kiso given in eq 2 is the same for the reactivation
model of Hugonnet and Blanchard13 and the conversion model
of Xu et al.,16 except k−2 is replaced by k3. However, the latter
model predicts that in time clavulanic acid will be degraded and
BlaC will regain activity, whereas the former model predicts
that an equilibrium is reached and BlaC will remain inhibited.
The latter model applies, as is discussed below.
The fits of the inhibition curves follow the data remarkably
accurately. However, variation of the parameters of the fit
shows that they are correlated and other combinations can be
obtained that yield equally accurate fits. To evaluate the quality
of the data and the values of the parameters, the data were also
simulated by solving the differential equations underlying the
kinetic model numerically using GNU Octave software. Good
simulations (Figure S6) were obtained with the values listed in
Table 2. All parameters are listed in Table S4. These
simulations show that curves contain small errors in the offset
and in the shape due to measuring artifacts, which are faithfully
fitted in the first approach. This suggests that the parameters
derived from the kiso curves may not be very accurate, due to
overfitting. It is clear, however, that the slopes of the last parts
of the curves (i.e., the vs values in eq 1) are close to zero in the
presence of high concentrations of clavulanic acid in MES
buffer, but not in phosphate buffer. This is reflected in the k3
value obtained in the simulations, which is much larger for the
inhibition in phosphate buffer than in MES buffer. The
phosphate buffer data cannot be simulated with the k3 values
obtained for the MES buffer data, indicating that this difference
is clearly significant. This finding implies that hydrolysis of
clavulanic acid by BlaC is much faster in phosphate buffer.
To test the rate of clavulanic acid hydrolysis in a more direct
manner, the recovery of activity after inhibition was assayed.
BlaC was incubated with a 5-fold excess of clavulanic acid, and
samples were taken over time and tested for nitrocefin
hydrolase activity. Enzyme activity was observed to return
after a characteristic delay time, reproducible over different
batches of enzyme and inhibitor but dependent on reaction
conditions (Figure 2, Table 3). At 20 μM BlaC with 100 μM
clavulanic acid in 100 mM MES pH 6.4, Hugonnet and
Blanchard13 observed no return of activity within 12 h. We find
that recovery occurs after ca. 14 h. Moreover, recovery was ca.
22 times faster in phosphate buffer than in MES buffer under
Figure 1. (a) Inhibition curves of BlaC nitrocefin hydrolysis with increasing concentrations of clavulanic acid in 100 mM NaPi, pH 6.4. Green lines
represent experimental data, black lines are fits using eq 1. (b) Plot of kiso values obtained from the fit of each inhibition curve against the respective
clavulanic acid concentration, for MES (red circles) as well as NaPi (black squares) buffer. The solid lines represent the fits to eq 2.
Table 2. Rate Constants of BlaC Inhibition with Clavulanic
Acida
approach Ki (μM) k2 (10
−2 s−1) k3 (10
−4 s−1)
NaPi pH 6.4 fit to eqs 1 and 2 32 ± 2 2.9 ± 0.1 4 ± 1
simulation 20 4.5 18
MES pH 6.4 fit to eqs 1 and 2 35 ± 4 4.9 ± 0.3 6 ± 3
simulation 20 4.5 0.25
aErrors represent the standard errors of the fit.
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the same conditions. Addition of sulfate to the MES buffer
resulted in ca. 7 times faster recovery, whereas addition of
acetate slowed the recovery down ca. 2.6 times. Turnover rates
were defined as the number of clavulanic acid molecules
inactivated per enzyme molecule per second and were derived
from the 50% recovery times. The turnover rates, listed in
Table 3, are close to those derived from the simulations of the
inhibition data (k3 values in Table 2). Interestingly, at a high
concentration of BlaC (300 μM), in 100 mM MES, recovery
was found to be about two times faster than that at 100 or 20
μM, with the same clavulanic acid-to-enzyme ratio of 5:1. To
investigate whether this was due to an allosteric effect of
clavulanic acid at high concentration, the recovery time was
measured for solutions with 100 μM BlaC and increasing
concentrations of clavulanic acid, from 100 to 1500 μM. The
total recovery time increased linearly with the concentration of
clavulanic acid (Figures S7 and S8), indicating that the turnover
rate of BlaC was constant. Thus, it is concluded that the
increase in turnover rate only occurs at very high BlaC
concentration (300 μM), perhaps due to a weak protein−
protein interaction. However, this effect is unlikely to be
relevant under physiological conditions and was not inves-
tigated further. No significant dependence of the turnover rate
was seen in phosphate buffer.
To gain insight in the inhibition intermediates that arise,
samples were analyzed using whole-protein mass spectrometry
(Figure 3). Before inhibition, the enzyme was present in three
forms, with the theoretical mass of BlaC as the main species
and minor additional species with relative masses of ca. −19
and −35 present. It is unclear how these latter two species differ
from the native enzyme or whether this is an artifact of the
sample treatment and MS analysis. Upon inhibition with
clavulanic acid, these peaks diminish and species of ca. +35,
+51, and +70 appear instead. The consistent relative intensities
and mass differences of +70 relative to the three unbound peaks
(−19 + 70 = +51; − 35 + 70 = +35) suggest that these peaks
represent a single inhibition intermediate. This is likely the
propionaldehyde ester that was previously reported upon
inhibition of BlaC with clavulanic acid.13,14 Several other peaks
also appear, including ca. +86, +136, and +154 species. The ca.
+86 intermediate has not been observed for inhibition of BlaC
with clavulanic acid before, but may correspond to the hydrated
propionaldehyde (+88) that was observed upon clavulanic acid
inhibition of related β-lactamases.12 The ca. +154 and +136
adducts were previously observed as BlaC clavulanic acid
intermediates, and these were proposed to represent a
decarboxylated trans-enamine adduct and its dehydrated
variant, respectively.13,14 Interestingly, although the observed
masses are similar to previous results, their relative intensities
are not. The BlaC +154 enamine was previously reported as the
major dead-end product. However, we observe mainly the +70
aldehyde adduct that was previously reported as minor and
decreasing over time. We observed only minor changes in
relative intensities upon prolonged incubation, even upon
incubating at higher clavulanic acid/BlaC ratios to achieve
higher turnover numbers (Figure 3, right). Instead, concurrent
with the return of activity, all species were observed to diminish
and the original masses returned. Remaining peaks could
indicate either irreversible inhibition products or incomplete
recovery, but these peaks were relatively low in intensity.
Furthermore, although the time required for enzyme recovery
was influenced greatly by the presence or absence of phosphate,
no effect on the type of intermediates was observed (Figure
S9).
As we found phosphate to promote recovery, we then sought
to characterize its interaction with BlaC. To further corroborate
the binding location in the active site, a BlaC crystal was soaked
in phosphate buffer and diffraction analysis was performed.
This yielded a 1.19 Å resolution structure, which is the highest
resolution obtained for BlaC to date. It is available in the
Protein Data Bank as entry 5NJ2.
The two protein molecules in the asymmetric unit each
display a well-resolved phosphate group with a conserved
position and orientation in the active site, at hydrogen bonding
distance from the Ser-70, Ser-130, Thr-235, and Thr-237
(Figure 4a). In both subunits, extra density is observed on the
oxygen moiety of the phosphate that is turned toward Ser-70
and the conserved active site water molecule, which could
indicate the presence of a hydrogen atom. However, we have
Figure 2. Example curves of BlaC recovery from clavulanic acid
inhibition. 20 μM BlaC was incubated with 100 μM clavulanic acid in
100 mM NaPi (black squares) or MES (red circles) buffer, pH 6.4.
Samples were taken at various time points, diluted to 2.0 nM BlaC and
tested for hydrolase activity using 100 μM nitrocefin. BlaC and
clavulanic acid separately were each stable throughout the experiments
(data not shown). The activity of inhibited enzyme is nonzero due to
recovery taking place in the time between initial dilution and activity
measurement of the samples (∼5 min).
Table 3. Rates of BlaC Activity Recovery from Clavulanic
Acid Inhibition
buffera
[BlaC]
(μM)
[clavulanic
acid] (μM) ratio
50% recovery
time (h)
turnover rate
(10−4 s−1)
MESb 20 100 1:5 14 ± 1 1.03 ± 0.07
MESc 100 100 1:1 1.8 ± 0.8 1.5 ± 0.7
MESc 100 300 1:3 7 ± 0.8 1.2 ± 0.1
MESc 100 500 1:5 13.8 ± 0.8 1.01 ± 0.06
MESc 100 1000 1:10 28 ± 0.8 0.99 ± 0.03
MESc 100 1500 1:15 43.5 ± 1 0.96 ± 0.02
MESd 300 1500 1:5 6.0 ± 0.6 2.3 ± 0.2
MES + 100
mM
acetic
acidc
100 500 1:5 36 ± 3 0.38 ± 0.03
MES + 100
mM
Na2SO4
c
100 500 1:5 2.0 ± 0.5 7 ± 2
NaPib 20 100 1:5 0.63 ± 0.06 22 ± 2
NaPid 300 1500 1:5 0.82 ± 0.01 16.8 ± 0.3
aBuffers were all 100 mM, pH 6.4. bErrors are the standard deviations
over four replicates. cErrors are the estimated error in half-time
determination of single experiments. dErrors are the standard
deviations over two replicates.
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not built this atom, because placement and refinement of
hydrogen atoms typically only occurs at resolutions better than
1.0 Å. Only one other phosphate group was modeled in the
crystal structure. This group is also well-resolved, but it does
not show any extra densities, further suggesting specificity of
the phosphate hydrogen bridge for the substrate binding site.
For comparison, BlaC was also crystallized in the presence of
acetate, without subsequent soaking with phosphate. This
yielded a 2.1 Å structure (Protein Data Bank entry 5OYO). It
shows that acetate occupies the carboxylate binding site and
forms hydrogen bridges with residues Ser-130, Thr-235, and
Figure 3. Charge-deconvoluted mass spectra of BlaC before and during incubation at 100 μM BlaC with 500 (left) or 1500 (right) μM clavulanic
acid in 100 mM MES, pH 6.4. Upon inhibition with clavulanic acid, the main species contain covalently bound adducts. After prolonged incubation,
the enzyme returns to its free form. The lowest spectra on either side correspond to recovered enzyme activity in the samples. The MS data were
obtained using a Waters Synapt mass spectrometer. Each spectrum was normalized to the total signal intensity.
Figure 4. Close-up on the carboxylate binding sites of BlaC crystal structures 5NJ2, chain A (a) and 5OYO chain B (b). Several catalytically
important residues and a conserved active site water molecule are indicated. Distances (in Å) of proposed hydrogen bridges (purple dashed lines)
involving the phosphate group and acetate are indicated in red. The mesh shows the 2Fo − Fc electron density map contoured at 1.5σ (a) or 1.0σ
(b).
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Thr-237 (Figure 4b). Unlike phosphate, it does not form a
hydrogen bridge with Ser-70.
To establish whether BlaC also interacts with phosphate in
the solution state, we used nuclear magnetic resonance
spectroscopy (NMR). As NMR studies of BlaC have not
been reported before, we recorded a set of standard three-
dimensional (3D) NMR spectra to perform sequential
backbone assignment. With these, 98% of the BlaC backbone
H−N moieties were assigned to a resonance peak in the
corresponding 1H−15N heteronuclear single quantum coher-
ence (HSQC) spectrum (Figure S10). Interestingly, the four
residues at hydrogen-bonding distance from the active site
phosphate (Figure 4a) were the only nonproline, nonterminal
residues whose backbone resonances could not be identified in
the spectra, suggesting that their amide nuclei are in
intermediate exchange, causing line broadening of the NMR
resonances. The assignment data are available at the Biological
Magnetic Resonance Bank under ID 27067.
We then acquired two-dimensional (2D) HSQC spectra of
BlaC at phosphate concentrations varying from 0−250 mM
(Figure S11). Multiple resonances were found to shift position,
indicating that the corresponding residues experience fast
exchange between different chemical environments. At low
phosphate concentrations only a few peaks were affected,
showing large chemical shift perturbations (CSPs), whereas
CSPs for many resonances were observed at higher phosphate
concentrations (>50 mM). When mapped on the protein
structure, it becomes apparent that the large CSPs arise for
Figure 5. BlaC−phosphate interaction. (a) Crystal structure 5NJ2 is shown with residues that are affected by phosphate binding in solution
highlighted. Residues of which the amide backbone experienced CSPs over 0.075, 0.10, and 0.15 ppm are displayed in yellow, orange, and red,
respectively, whereas the ones for which no data were available are displayed in gray and those with no or small CSPs are colored green. The
phosphate as observed in the crystal structure is indicated in red. (b) Binding curves. The plot shows the CSPs upon phosphate titration for five
selected amide resonances plotted against the ratio of the phosphate and BlaC concentrations. Data points are shown with an estimated peak picking
error of ±0.02 ppm, error in KD is the standard deviation over duplicate titrations.
Figure 6. Effect of clavulanic acid on BlaC as measured by NMR. (a) Crystal structure 3CG5,14 highlighting residues of which NMR resonances are
affected by addition of clavulanic acid. Residues of which the amide backbone resonance experienced CSPs over 0.01 ppm and over 0.05 ppm are
displayed in yellow and red, respectively, while the ones for which no data were available are displayed in gray and the remaining residues in green.
The bound reacted adduct of clavulanic acid as was observed by Tremblay et al.14 is shown in purple sticks. (b) Effect of clavulanic acid on BlaC over
time, in 100 mM MES (red circles) and NaPi (black squares) buffer, pH 6.4. Data points show average and standard deviation of relative signal
intensities from the native (open symbols) and inhibited (filled symbols) resonances of residues Cys-69, Ala-74, Asp-131, Ala-146, and Tyr-241.
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nuclei close to the position in the active site where phosphate is
present in the crystal structure (Figure 5, left). The smaller
CSPs that appear at high phosphate concentration represent
much weaker phosphate binding at other sites. The data
allowed us to determine the binding affinity in solution. By
analyzing the magnitude of active-site CSPs as a function of the
phosphate/BlaC ratio, a binding affinity (KD) of 27 ± 11 mM
was found for phosphate binding to BlaC (Figure 5, right). A
separate titration with sodium chloride (Figure S12) did not
result in any CSPs with the magnitude, colocalization, or
affinity of those found for phosphate, confirming that the
observed effects are caused by a specific interaction.
NMR spectroscopy was also used to study the BlaC−
clavulanic acid interaction. Upon addition of a 5-fold excess of
clavulanic acid, several peaks disappeared and new peaks
appeared nearby. Unsurprisingly, the corresponding nuclei were
located in the active site (Figure 6a). Upon prolonged
incubation, the peaks of the unbound state reappeared and
the peaks of the bound state disappeared. This observation
indicates that the free and bound forms are not in exchange on
the chemical shift time scale (exchange rate ≪100 s−1), in line
with the expected formation of a covalent intermediate. The
recovery times of free BlaC after incubation with 5-fold excess
of clavulanic acid based on the NMR peak intensities (Figure
6b) were in agreement with the kinetics and MS data (Table 3),
including data taken directly on the NMR samples.
■ DISCUSSION
In this work, BlaC and its interaction with clavulanic acid were
further characterized in vitro. The Michaelis−Menten kinetic
values found for nitrocefin hydrolysis are largely consistent with
previous observations, although an elevation of the Michaelis
constant was observed in the presence of phosphate. This may
point toward competition between phosphate and substrate for
occupation of the carboxylate binding site. This explanation
would lend further credence to the suggestion by Kurz et al.36
that the same competition may explain their observation of an
oddly placed carbonyl moiety in cocrystallization of BlaC with a
boronic acid transition state inhibitor. To determine the
reaction rates with clavulanic acid, the model proposed by Xu et
al.16 was used (eq 7). It should be noted that clavulanic acid
chemistry may be more complicated than this model suggests,
as various inhibition intermediates have been reported13,14 and
observed in this study. Presumably, different inhibition
intermediates will have different rates of formation and
decomposition.
The approach of fitting inhibition curves to initial and final
velocities (vi and vs) and an exponential decay constant (kiso)
that describes the time to reach a steady state inhibition level
has been used frequently. Our simulations of the curves suggest
that the method may lead to overfitting of the parameters and
should be used with caution. In particular the rate constant for
hydrolysis of the covalent intermediate (k3) is poorly defined.
This rate is very low and its value depends heavily on the fits of
the lowest inhibitor concentrations. The parameters of
clavulanic acid inhibition onset that we found are in reasonable
agreement with the Ki = 12.1 μM and k2 = 2.7 s
−1 found by
Hugonnet and Blanchard,13 who used the same approach
described here except for their assumption that the covalent
intermediate is not hydrolyzed (k3 = 0). We found that BlaC
slowly converts clavulanic acid to regain activity, consistent with
the observations of Xu et al.16 The return to the native active
form of the protein was demonstrated by activity assays, NMR
spectroscopy, and mass spectrometry.
The main covalent intermediate of inhibition was observed
to harbor a ca. + 70 mass compared to the noninhibited
protein, corresponding to the adducts observed by Hugonnet
and Blanchard13 upon inhibition with each of the inhibitors
clavulanic acid, sulbactam, and tazobactam and proposed by
them and others to be a hydrolyzable aldehyde adduct.
However, the +136 and +154 clavulanic acid enamine adducts
observed as main, dead-end, reaction products by Hugonnet
and Blanchard13 as well as Xu et al.14 were observed in only
minor quantities in our analysis. We demonstrate that the rate
of recovery is highly dependent on reaction conditions.
Phosphate ions enhance the rate, yet the composition of the
inhibition intermediates is not affected. This indicates that
phosphate promotes the release of covalently bound clavulanic
acid adducts from the active site and does not change the
direction of the initial chemistry. NMR experiments support
phosphate ion binding in the active site and show that the
dissociation constant is 3 × 10−2 M. This affinity requires that
at crystallization conditions of 2 M phosphate, the site should
be fully occupied. This is consistent with the observations
published so far. We note that structure 2GDN is the only BlaC
structure that was modeled with an empty carboxylate binding
site, despite a high phosphate concentration in the crystal-
lization buffer, but the data do show density that suggests the
presence of a phosphate ion there. Our high resolution
structure shows that the phosphate is in hydrogen bond
distance to several important active site residues and may be
protonated at the phosphate oxygen close to Ser-70.
To formulate a hypothesis about the role of phosphate in
promoting hydrolysis, we examined the structure of BlaC
covalently bound to a cleavage product of clavulanic acid (PDB
entry 3CG5,14 Figure 7). It should be noted that the
intermediate in structure 3CG5 is not the dominant species
observed in our work, of +70 Da, but the ester bond to Ser-70
is likely to be in a similar place in all intermediates. In this
Figure 7. Schematic representation of catalytically important groups
and their hydrogen-bonding network, as present in structure 3CG514
of BlaC with a clavulanic acid cleavage product (indicated in blue)
covalently bound to Ser-70. Distances (in Å) between heavy atoms
involved in potential H-bonds are shown in red. Residues are
numbered according to the Ambler consensus,11 and other numbers
represent the internal numbering of the published structure.
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structure, a phosphate (PO4 309) is present in the same
location as in the structure of substrate free BlaC, although it is
slightly displaced by the presence of the adduct. Most likely, the
carboxylate binding site is also involved in the initial interaction
between BlaC and the carboxy group of clavulanic acid, but it
becomes available upon decarboxylation of the acyclic adduct.
This reaction occurs rapidly and appears to create enough space
to allow for diffusion of phosphate into the carboxylate binding
site. In the second step of the reaction, a nucleophilic attack on
the carbon (atom CAG in structure 3CG5) of the adduct
forming the ester bond with Ser-70 occurs, the bond between
Ser-70 and the adduct is broken, and Ser-70 Oγ is reprotonated.
The nucleophilic attack can be executed by water 441, located
at 3.1 Å underneath the ester bond plane and hydrogen bonded
to Glu-166. This is the standard mechanism of β-lactamase
hydrolysis. However, O3 of the phosphate is located also at 3.1
Å of the CAG carbon and right above the ester bond plane. So,
alternatively, the phosphate could carry out the nucleophilic
attack. After release from the enzyme, the phospho-adduct
would probably be rapidly hydrolyzed.
An alternative role of the phosphate could be in
reprotonation of the Ser-70 Oγ. The distance between the
phosphate oxygen O3 and the Ser-70 Oγ is larger (3.5 Å) than
in the substrate-free structure (2.9 Å, Figure 4a), but it is close
to the Oγ of Ser-130 (2.5 Å). If the nucleophilic attack is
performed by the water, a proton would be donated to Glu-
166. This glutamate is hydrogen bonded to the amine of Lys-
73, which also forms an H-bond with Ser-70 Oγ, allowing for
proton transfer to Ser. Alternatively, the Ser-70 Oγ could be
reprotonated by accepting the proton from Ser-130 (O−O
distance 2.7 Å), which in its turn accepts a proton from O3 of
the phosphate (Figure 7). The phosphate is in contact with
waters on the protein surface (HOH 492, 500, and 516). In this
case, Glu-166 could release its proton by a flip of the carboxy
group and donation of a proton to the nearby water chain
(HOH 586 and HOH 587).
Our data show that sulfate can also accelerate hydrolysis of
clavulanic acid, albeit less than phosphate. It can be expected
that the sulfate ion is fully deprotonated at pH 6.4, so it could
not act as a hydrogen donor to Ser-130. However, it could act
as a nucleophile to attack carbon CAG. One BlaC structure,
PDB 3ZHH,37 shows sulfate bound in the carboxylate binding
site, in a similar location as the phosphate. The limited
resolution does not allow for a detailed analysis. We also solved
the structure of BlaC with excess acetate. Acetate in MES buffer
has a negative effect on the hydrolysis rate as compared to MES
buffer only. This observation cannot be readily explained, but
the data show acetate binding in the carboxylate binding site. It
forms a hydrogen bond with Ser-130, so could act as a
hydrogen bond donor. In an overlay of 3CG5 and our structure
5OYO, it can be seen that the closest oxygen of the acetate is at
4.2 Å of the CAG carbon, making a nucleophilic attack unlikely.
We cannot exclude that MES buffer (2-(N-morpholino)-
ethanesulfonic acid) can bind to the carboxylate binding site
as well, via its sulfonate group, having a weak positive effect on
the rate of hydrolysis. Acetate could be competing with MES,
leading to a reduction of the rate. These considerations point to
a role of phosphate and sulfate as alternative nucleophiles. We
emphasize, however, that the proposed mechanisms are
speculative. Further research is required to understand the
influence of anions on the hydrolysis rate of clavulanic acid.
Clearly, the binding site is promiscuous, and various ions have
quite different effects on hydrolysis.
It is worthwhile to consider whether the effect we observe is
specific for BlaC, or if it may signify a more general mechanism
in class A β-lactamases. Indeed, related proteins such as TEM-1,
SHV-1, and CTX-M-1 have very similar carboxylate binding
sites. However, most of these enzymes harbor an Ala at position
237, where BlaC has a Thr, which contributes a hydrogen bond
to the binding of phosphate (Figure 4a). Indeed, although
phosphates and sulfates have been observed to occupy
analogous positions in at least TEM-1,38 CTX-M-9,39 and
L2,40 many X-ray structures of these enzymes with empty
carboxylate binding site have also been reported (e.g., structure
3CMZ41 of TEM-1 and structure 1SHV42 of SHV-1). These
observations suggest that the affinities between these proteins
and phosphate-like groups may be lower than in the case of
BlaC. We therefore expect any effect of phosphate in related
enzymes to be less significant. Whether the role of phosphate
and other anions in the breakdown of clavulanic acid by BlaC is
relevant under physiological conditions is unclear. M. tuber-
culosis is known to prevent maturation of lysosomes by blocking
phagolysosomal fusion and has been shown to live at slightly
acidic pH.43 The experiments reported here have been
conducted at pH 6.4, which is the optimal pH of BlaC and
can thus be expected to be physiologically relevant. The
concentration of phosphate ions in M. tuberculosis within
macrophages is unknown. Total prokaryotic and eukaryotic
intracellular phosphate ion concentrations, however, are in the
1−10 mM range.44 Additionally, sulfate ions were observed to
have a similar effect, and it cannot be excluded that other
compounds, such as ATP, can also interact with BlaC. Thus, it
is reasonable to expect that a substantial fraction of BlaC
molecules binds a phosphate-like group specifically in the active
site.
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